Literature DB >> 18594325

Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer.

Peter J Mazzone1.   

Abstract

Volatile organic compounds are able to be detected in the exhaled breath by a variety of sensing techniques. These volatiles may be produced by cellular metabolic processes, or inhaled/absorbed from exogenous sources. Lung cancer cells may produce and process these compounds different than normal cells. The differences may be detectable in the breath. The following manuscript will review the evidence supporting the premise that a unique chemical signature can be detected in the breath of patients with lung cancer, discuss the results of studies using mass spectrometry and nonspecific chemical sensing techniques to detect the unique lung cancer signature, and speculate on the advancements that must occur to develop a breath test accurate enough to be clinically useful.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594325     DOI: 10.1097/JTO.0b013e31817c7439

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  34 in total

Review 1.  Lung cancer screening: an update, discussion, and look ahead.

Authors:  Peter J Mazzone
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 2.  Lung cancer screening: past, present and future.

Authors:  James H Finigan; Jeffrey A Kern
Journal:  Clin Chest Med       Date:  2013-07-23       Impact factor: 2.878

3.  Nanomedicine: Sniffing out lung cancer.

Authors:  Peter Mazzone
Journal:  Nat Nanotechnol       Date:  2009-10       Impact factor: 39.213

4.  Bronchoscopically obtained volatile biomarkers in lung cancer.

Authors:  Kaid Darwiche; Joerg Ingo Baumbach; Urte Sommerwerck; Helmut Teschler; Lutz Freitag
Journal:  Lung       Date:  2011-10-04       Impact factor: 2.584

Review 5.  The state of molecular biomarkers for the early detection of lung cancer.

Authors:  Mohamed Hassanein; J Clay Callison; Carol Callaway-Lane; Melinda C Aldrich; Eric L Grogan; Pierre P Massion
Journal:  Cancer Prev Res (Phila)       Date:  2012-06-11

6.  Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Authors:  Jens Köhler; Martin Schuler; Thomas Christoph Gauler; Stefanie Nöpel-Dünnebacke; Maike Ahrens; Andreas-Claudius Hoffmann; Stefan Kasper; Felix Nensa; Benedikt Gomez; Maria Hahnemann; Frank Breitenbuecher; Danjouma Cheufou; Filiz Özkan; Kaid Darwiche; Mathias Hoiczyk; Henning Reis; Stefan Welter; Wilfried Ernst Erich Eberhardt; Martin Eisenacher; Helmut Teschler; Georgios Stamatis; Wolff Schmiegel; Stephan Albrecht Hahn; Alexander Baraniskin
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-19       Impact factor: 4.553

Review 7.  Clinical application of volatile organic compound analysis for detecting infectious diseases.

Authors:  Shneh Sethi; Ranjan Nanda; Trinad Chakraborty
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

8.  Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process.

Authors:  Tatjana Abaffy; Robert Duncan; Daniel D Riemer; Olaf Tietje; George Elgart; Clara Milikowski; R Anthony DeFazio
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

9.  Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors.

Authors:  G Peng; M Hakim; Y Y Broza; S Billan; R Abdah-Bortnyak; A Kuten; U Tisch; H Haick
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

Review 10.  Carbon monoxide in exhaled breath testing and therapeutics.

Authors:  Stefan W Ryter; Augustine M K Choi
Journal:  J Breath Res       Date:  2013-02-27       Impact factor: 3.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.